Synthego has tapped Eurofins Genomics to distribute synthetic single guide RNA products from its CRISPRevolution line of genome-editing kits.
LEO Pharma signed on to a research collaboration with PellePharm that commits up to $760 million for late-stage trials, including a merger option.
In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In…
Eli Lilly VP Robert Brown is making the jump to serve as CEO of the skin disease-focused Brickell Biotech.
Merck KGaA is launching a new joint venture with the tech firm Palantir, built around a collaboration platform for cancer research and discovery.
A phase 3 study from imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in glioma diagnoses.
In rodent studies, exon skipping corrected a genetic error that's responsible for kidney disease linked to Joubert syndrome.
Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.
Results from Aimmune’s phase 3 trial of AR101 for peanut allergy have been published and bode well for its planned FDA filing next month.
The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases.
The deal gives the Roche subsidiary at least a partial stake in the preclinical MAGE-A4-targeting drug IMC-C103C.